| pubmed-article:12384531 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12384531 | lifeskim:mentions | umls-concept:C0026809 | lld:lifeskim |
| pubmed-article:12384531 | lifeskim:mentions | umls-concept:C0302600 | lld:lifeskim |
| pubmed-article:12384531 | lifeskim:mentions | umls-concept:C1458155 | lld:lifeskim |
| pubmed-article:12384531 | lifeskim:mentions | umls-concept:C0970963 | lld:lifeskim |
| pubmed-article:12384531 | lifeskim:mentions | umls-concept:C0206364 | lld:lifeskim |
| pubmed-article:12384531 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
| pubmed-article:12384531 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
| pubmed-article:12384531 | lifeskim:mentions | umls-concept:C0205276 | lld:lifeskim |
| pubmed-article:12384531 | lifeskim:mentions | umls-concept:C0162768 | lld:lifeskim |
| pubmed-article:12384531 | lifeskim:mentions | umls-concept:C0033972 | lld:lifeskim |
| pubmed-article:12384531 | lifeskim:mentions | umls-concept:C1999216 | lld:lifeskim |
| pubmed-article:12384531 | pubmed:issue | 20 | lld:pubmed |
| pubmed-article:12384531 | pubmed:dateCreated | 2002-10-17 | lld:pubmed |
| pubmed-article:12384531 | pubmed:abstractText | The therapeutic efficacy of combined antiangiogenic and immune therapy was tested against weakly immunogenic and highly metastatic 4T1 breast tumor using SU6668, an angiogenesis inhibitor and recombinant murine (rm) B7.2-IgG fusion protein, an immunostimulator. SU6668 inhibits the tyrosine kinase activity of three angiogenic receptors VEGFR2 (Flk-1/KDR), PDGFRbeta, and FGFR1, which play a crucial role in tumor-induced vascularization. rmB7.2-IgG is a fusion protein of the extracellular domain of B7.2, and the hinge and constant domains of murine IgG2a. Intermolecule disulfide linkages are maintained so that it forms a dimer. Our studies showed that three weekly immunizations of BALB/c mice bearing 0.5-0.8 cm 4T1 breast tumors with rmB7.2-IgG and irradiated 4T1 tumor cells (B7.2-IgG/TC) resulted in a significant inhibition of tumor growth and formation of pulmonary metastases. T-cell depletion experiments revealed that both CD4(+) and CD8(+) T lymphocytes are required for stimulation of the antitumor and antimetastatic immune response by B7.2-IgG/TC. Treatment of mice with SU6668 substantially inhibited tumor vascularization but did not inhibit tumor infiltration by T lymphocytes or the T-cell response to rmB7.2-IgG therapy. On the contrary, tumors in mice immunized with B7.2-IgG/TC and treated with SU6668 had higher numbers of tumor infiltrating T cells than tumors of other groups. SU6668 treatments initiated either on day 3 or day 10 after inoculation of 4T1 tumor cells resulted in a significant inhibition of tumor growth. Similarly, three weekly immunizations with B7.2-IgG/TC starting either on day 7 or 12 inhibited growth of 4T1 tumors. However, the most potent antitumor effects were observed in mice treated with a combination of SU6668 and B7.2-IgG/TC. Analysis of pulmonary metastases revealed that combined therapy also had a more potent antimetastatic effect than each modality alone. These results indicate that antiangiogenic and immune therapies using SU6668 and B7.2-IgG/TC are compatible, and manifest complementary antitumor and antimetastatic effects. Combined antiangiogenic and immune therapy might represent a new strategy for cancer treatment. | lld:pubmed |
| pubmed-article:12384531 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12384531 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12384531 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12384531 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12384531 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12384531 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12384531 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12384531 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12384531 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12384531 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12384531 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12384531 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12384531 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12384531 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12384531 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12384531 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12384531 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12384531 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12384531 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:12384531 | pubmed:issn | 0008-5472 | lld:pubmed |
| pubmed-article:12384531 | pubmed:author | pubmed-author:LairdA... | lld:pubmed |
| pubmed-article:12384531 | pubmed:author | pubmed-author:WatkinsSimonS | lld:pubmed |
| pubmed-article:12384531 | pubmed:author | pubmed-author:HuangXiaojunX | lld:pubmed |
| pubmed-article:12384531 | pubmed:author | pubmed-author:GorelikEliese... | lld:pubmed |
| pubmed-article:12384531 | pubmed:author | pubmed-author:WongMichael... | lld:pubmed |
| pubmed-article:12384531 | pubmed:author | pubmed-author:YiHuimingH | lld:pubmed |
| pubmed-article:12384531 | pubmed:author | pubmed-author:WolfStanley... | lld:pubmed |
| pubmed-article:12384531 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12384531 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:12384531 | pubmed:volume | 62 | lld:pubmed |
| pubmed-article:12384531 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12384531 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12384531 | pubmed:pagination | 5727-35 | lld:pubmed |
| pubmed-article:12384531 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:12384531 | pubmed:meshHeading | pubmed-meshheading:12384531... | lld:pubmed |
| pubmed-article:12384531 | pubmed:meshHeading | pubmed-meshheading:12384531... | lld:pubmed |
| pubmed-article:12384531 | pubmed:meshHeading | pubmed-meshheading:12384531... | lld:pubmed |
| pubmed-article:12384531 | pubmed:meshHeading | pubmed-meshheading:12384531... | lld:pubmed |
| pubmed-article:12384531 | pubmed:meshHeading | pubmed-meshheading:12384531... | lld:pubmed |
| pubmed-article:12384531 | pubmed:meshHeading | pubmed-meshheading:12384531... | lld:pubmed |
| pubmed-article:12384531 | pubmed:meshHeading | pubmed-meshheading:12384531... | lld:pubmed |
| pubmed-article:12384531 | pubmed:meshHeading | pubmed-meshheading:12384531... | lld:pubmed |
| pubmed-article:12384531 | pubmed:meshHeading | pubmed-meshheading:12384531... | lld:pubmed |
| pubmed-article:12384531 | pubmed:meshHeading | pubmed-meshheading:12384531... | lld:pubmed |
| pubmed-article:12384531 | pubmed:meshHeading | pubmed-meshheading:12384531... | lld:pubmed |
| pubmed-article:12384531 | pubmed:meshHeading | pubmed-meshheading:12384531... | lld:pubmed |
| pubmed-article:12384531 | pubmed:meshHeading | pubmed-meshheading:12384531... | lld:pubmed |
| pubmed-article:12384531 | pubmed:meshHeading | pubmed-meshheading:12384531... | lld:pubmed |
| pubmed-article:12384531 | pubmed:meshHeading | pubmed-meshheading:12384531... | lld:pubmed |
| pubmed-article:12384531 | pubmed:meshHeading | pubmed-meshheading:12384531... | lld:pubmed |
| pubmed-article:12384531 | pubmed:meshHeading | pubmed-meshheading:12384531... | lld:pubmed |
| pubmed-article:12384531 | pubmed:meshHeading | pubmed-meshheading:12384531... | lld:pubmed |
| pubmed-article:12384531 | pubmed:meshHeading | pubmed-meshheading:12384531... | lld:pubmed |
| pubmed-article:12384531 | pubmed:meshHeading | pubmed-meshheading:12384531... | lld:pubmed |
| pubmed-article:12384531 | pubmed:meshHeading | pubmed-meshheading:12384531... | lld:pubmed |
| pubmed-article:12384531 | pubmed:meshHeading | pubmed-meshheading:12384531... | lld:pubmed |
| pubmed-article:12384531 | pubmed:meshHeading | pubmed-meshheading:12384531... | lld:pubmed |
| pubmed-article:12384531 | pubmed:meshHeading | pubmed-meshheading:12384531... | lld:pubmed |
| pubmed-article:12384531 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:12384531 | pubmed:articleTitle | Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein. | lld:pubmed |
| pubmed-article:12384531 | pubmed:affiliation | Department of Pathology and University of Pittsburgh Cancer Institute, Pennsylvania 15213, USA. | lld:pubmed |
| pubmed-article:12384531 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12384531 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:12384531 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| pubmed-article:12384531 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12384531 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12384531 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12384531 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12384531 | lld:pubmed |
